Free Trial
NASDAQ:AFIB

Acutus Medical (AFIB) Stock Price, News & Analysis

Acutus Medical logo
$0.05 0.00 (-7.59%)
As of 02/21/2025 03:54 PM Eastern

About Acutus Medical Stock (NASDAQ:AFIB)

Key Stats

Today's Range
$0.05
$0.06
50-Day Range
$0.04
$0.07
52-Week Range
$0.03
$0.27
Volume
48,095 shs
Average Volume
48,442 shs
Market Capitalization
$1.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Acutus Medical, Inc. designs, manufactures, and markets various tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. Its product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. Acutus Medical, Inc. was incorporated in 2011 and is headquartered in Carlsbad, California.

Receive AFIB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acutus Medical and its competitors with MarketBeat's FREE daily newsletter.

AFIB Stock News Headlines

Acutus Medical Announces Operational Downsizing
Acutus Medical Reports Q3 2024 Financial Results
Elon Takes Aim at Social Security
Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social Security, finding what he says is widespread fraud across the agency.
See More Headlines

AFIB Stock Analysis - Frequently Asked Questions

Acutus Medical's stock was trading at $0.0550 at the beginning of the year. Since then, AFIB shares have decreased by 2.5% and is now trading at $0.0536.
View the best growth stocks for 2025 here
.

Acutus Medical, Inc. (NASDAQ:AFIB) released its earnings results on Thursday, November, 11th. The company reported ($0.94) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.92) by $0.02. The business had revenue of $4.60 million for the quarter, compared to analysts' expectations of $6.02 million. Acutus Medical had a negative trailing twelve-month return on equity of 311.64% and a negative net margin of 272.74%.

Acutus Medical subsidiaries include Acutus Medical N.V..

Acutus Medical (AFIB) raised $126 million in an IPO on Thursday, August 6th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, BofA Securities and William Blair served as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

Shares of AFIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Acutus Medical investors own include Enterprise Products Partners (EPD), NVIDIA (NVDA), Arista Networks (ANET), Meta Platforms (META), Nextera Energy Partners (NEP), PayPal (PYPL) and Rio Tinto Group (RIO).

Company Calendar

Last Earnings
11/11/2021
Today
2/22/2025
Next Earnings (Estimated)
3/31/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:AFIB
Employees
340
Year Founded
2011

Profitability

Net Income
$-81,660,000.00
Net Margins
-272.74%
Pretax Margin
-30.32%

Debt

Sales & Book Value

Annual Sales
$7.16 million
Book Value
($0.03) per share

Miscellaneous

Free Float
28,228,000
Market Cap
$1.60 million
Optionable
Optionable
Beta
-0.18

Social Links

20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (NASDAQ:AFIB) was last updated on 2/22/2025 by MarketBeat.com Staff
From Our Partners